Avid Bioservices, Inc.
CDMO · NASDAQ
4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -19.83 | 0.00 | -0.77 |
| FCF Yield | -4.32% | -8.19% | -5.67% | 1.71% |
| EV / EBITDA | -56.78 | 115.17 | 44.41 | 76.10 |
| Quality | ||||
| ROIC | -36.32% | -0.14% | 30.63% | 4.52% |
| Gross Margin | 5.23% | 21.09% | 30.64% | 30.57% |
| Cash Conversion Ratio | -0.08 | -23.01 | 0.07 | 2.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.37% | 15.90% | 26.06% | 21.38% |
| Free Cash Flow Growth | 76.96% | -92.83% | -320.22% | 957.97% |
| Safety | ||||
| Net Debt / EBITDA | -14.78 | 13.81 | 2.83 | -3.30 |
| Interest Coverage | -4.31 | -0.87 | 4.05 | 7.67 |
| Efficiency | ||||
| Inventory Turnover | 4.37 | 2.68 | 3.18 | 5.61 |
| Cash Conversion Cycle | 102.40 | 128.10 | 151.95 | 109.34 |